Print PDF
Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022

Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.